An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma
Abstract
ALK is a tractable antibody-drug conjugate target in neuroblastoma.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 13, 2019
- Source ID
- 10.1126/scitranslmed.aau9732
Entities
People
- Bruce Pawel
- Colleen E. Larmour
- Daniel Martinez
- Diego Alvarado
- Gwenda F. Ligon
- Jay S. Lillquist
- Kateryna Krytska
- Paolo Orsini
- Pichai Raman
- Renata Sano
- Simona Rizzi
- Ulisse Cucchi
- Yael P. Mossé
Organizations
- Children's Hospital of Philadelphia
- United States Department of Defense
- University of Pennsylvania